Kymriah, All Checkpoint Drugs but Tecentriq to Get Price Maintenance Premium in October Re-Pricing

August 20, 2019
A total of 339 innovative APIs/591 products will be granted the price maintenance premium (PMP) in Japan’s ad-hoc re-pricing associated with the consumption tax hike in October, with Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) and all immune checkpoint inhibitors other than...read more